Currently Viewing:
Evidence-Based Oncology June 2020
Currently Reading
References for Humility and Hope, Alvarnas
Joseph Alvarnas, MD
How to Optimize Cancer Therapy When Coronavirus Hits the Fan
Afsaneh Barzi, MD, PhD, and Sarmad Sadeghi, MD, PhD
Addressing the Gap in Precision Medicine
David A. Fabrizio, BS
Conference Coverage: Community Oncology Alliance
Maggie L. Shaw and Mary Caffrey
Conference Coverage: AACR, AMCP, ISPOR
AJMC Staff
Medical World News: June 2020 Managed Care, Clinical Updates
Coverage by Gianna Melillo and Jared Kaltwasser
Humility and Hope: Evolution of the HIV Pandemic, From ART to Today's Cancer Cures
Joseph Alvarnas, MD
From the Editor-in-Chief: Bigger Questions of Systems, Viruses, and the Lives of Real People
Joseph Alvarnas, MD

References for Humility and Hope, Alvarnas

Joseph Alvarnas, MD
References:  Humility and Hope: Evolution of the HIV Pandemic, From ART to Today’s Cancer Cures
1. Lawrence TE (story). Bolt R, Wilson M (screenplay). Lawrence of Arabia [film]. United Kingdom: Horizon Pictures; 1962.

2. CDC. Pneumocystis pneumonia — Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250-252.

3. CDC. First report of AIDS. MMWR Morb Mortal Wkly Rep. 2001;50(21):429.

4. du Bois RM, Branthwaite MA, Mikhail JR, Batten JC. Primary Pneumocystis carinii and cytomegalovirus infections. Lancet. 1981;318(8259):1339. doi:10.1016/S0140-6736(81)91353-2

5. Pickrell J. Timeline: HIV and AIDS. New Scientist. September 4, 2006. Accessed May 19, 2020.

6. A timeline of HIV and AIDS. Accessed May 19, 2020.

7. CDC. Current trends update on Acquired Immune Deficiency Syndrome (AIDS)—United States. MMWR Morb Mortal Wkly Rep. 1982;31(37):507-508, 513-514.

8. Altman LK. New U.S. report names virus that may cause AIDS. The New York Times. April 24, 1984. Accessed May 19, 2020.

9. History of HIV and AIDS overview. Avert. Updated October 10, 2019. Accessed May 23, 2020.

10. Sharp P, Hahn BH. The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci. 2010;365(1552):2487-2494. doi:10.1098/rstb.2010.0031

11. Fehervari Z. Origin story. Nature Research. November 28, 2018. Accessed May 23, 2020.

12. CNN. Researchers trace first HIV case to 1959 in the Belgian Congo. CNN Interactive. February 3, 1998. Accessed May 23, 2020.

13. Sharp P, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1(1):a006841. doi:10.1101/cshperspect.a006841 

14. Hendrix S. A mystery illness killed a boy in 1969. years later, doctors believed they’d learned what it was: AIDS. The Washington Post. May 15, 2019. Accessed May 23, 2020.

15. Global Health Observatory (GHO) data: HIV/AIDS. World Health Organization. Accessed May 23, 2020.

16. CDC. Update: trends in AIDS incidence – United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(37);861-867.

17. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167-1170. doi:10.1126/science.272.5265.1167

18. Feinberg MB. Changing the natural history of HIV disease. Lancet. 1996;348(9022):239-246. doi:10.1016/s0140-6736(96)06231-9

19. Vella S. XI International AIDS Conference: new antiretroviral therapy guidelines. NEJM Journal Watch. October 1, 1996. Accessed May 19,


20. Scaccia A, Madell R. Facts about HIV: life expectancy and long-term outlook. Healthline. Reviewed April 27, 2018. Accessed May 23, 2020.

21. HIV mortality slide series through 2015. CDC Stacks Public Health Publications. August 13, 2018. Accessed May 23, 2020.

22. AIDS drugs have saved 3 million years of life in the United States. News release. National Institute of Allergy and Infectious Diseases; June 2,

2006. Accessed May 23, 2020.

23. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med.

2009;360(7):692-698. doi:10.1056/NEJMoa0802905

24. Mandavilli A. The ‘London Patient,’ cured of HIV, reveals his identity. The New York Times. Published March 9, 2020. Accessed May 23, 2020.

25. Bavinton BR, Rodger AJ. Undetectable viral load and HIV transmission dynamics on an individual and population level: where next in the

global HIV response? Curr Opin Infect Dis. 2020;33(1):20-27. doi:10.1097/QCO.0000000000000613

26. Reitsema M, van Hoek AJ, van der Loeff MS, et al. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness. AIDS. 2020;34(4):621-630. doi:10.1097/QAD.0000000000002469

27. Selik RM, Mokotoff ED, Branson B, et al. Revised surveillance case definition for HIV infection — United States, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(RR03):1-10.

28. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60(12):1365-1372. doi:10.1136/jcp.2007.051953

29. Achenbach CJ, Buchanan AL, Cole SR, et al; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014;58(11):1599-1606. doi:10.1093/cid/ciu076 

30. Levine AM. Acquired immunodeficiency syndrome–related lymphoma. Blood. 1992;80(1):8-20.

31. Vishnu P, Aboulafia DM. AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy. Adv Hematol. 2012;2012:485943. doi:10.1155/2012/485943

32. Swiss HIV Cohort Study; Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort Study. Int J Epidemiol. 2010;39(5):1179-1189. doi:10.1093/ije/dyp321

33. Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort Study. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425-432. doi:10.1093/jnci/dji072

34. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma. histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol. 1991;138(1):149-163.

35. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(23):1641-1648. doi:10.1056/NEJM199706053362304

36. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trials of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24(25):4123-4128. doi:10.1200/JCO.2005.05.4684

37. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543. doi:10.1182/blood-2005-04-1437

38. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral suspension and tumor biology. Blood. 2003;101(12):4653-4659. doi:10.1182/blood-2002-11-3589

39. Sparano JA, Lee JY, Kaplan LD, et al; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008-2016. doi:10.1182/blood-2009-08-231613

40. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SCEPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024. doi:10.1182/blood-2009-11-253039

41. Noy A, Kaplan L, Lee JY. A modified dose intensive R- CODOX-M/IVAC for HIV-associated Burkitt lymphoma and atypical Burkitt lymphoma (BL) demonstrates high cure rates and low toxicity: prospective multicenter trial of the AIDS Malignancy Consortium (AMC 048). Blood. 2013;122(21):639. doi:10.1182/blood.V122.21.639.639

42. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012;2012:735392. doi:10.1155/2012/735392

43. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS. 2010;24(6):851-856. doi:10.1097/QAD.0b013e3283301578

44. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome–related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492-1499.


45. Kojima Y, Hagiwara S, Uehira T, et al. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan. Jpn J Clin Oncol. 2014;44(4):318-323. doi:10.1093/jjco/hyu012

46. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915-1925.  doi:10.1056/NEJMoa1308392

47. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associate non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-3262. doi:10.1182/blood-2013-04-498964

48. Alvarnas JC, Le Rademacher J, Wang Y, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016;128(8):1050-1058. doi:10.1182/blood-2015-08-664706

49. Ambinder RF, Wu J, Logan B, et al. Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 Trial. Biol Blood Marrow Transplant. 2019;25(11):2160-2166. doi:10.1016/j.bbmt.2019.06.033

50. Alvarnas JC, Zaia JA, Forman SJ. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. Blood. 2017;130(18):1976-1984. doi:10.1182/blood-2017-04-551606

51. Division of HIV/AIDS Prevention. Statistic overview. CDC. Updated May 18, 2020. Accessed May 23, 2020.

52. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med. 2012;2(1):a007039. doi:10.1101/cshperspect.a007039

53. Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature.

2015;517(7534):381-385. doi:10.1038/nature14053

54. Harris JE. Why we don’t have an HIV vaccine, and how we can develop one. Health Aff (Millwood). 2009;28(6):1642-1654. doi:10.1377/hlthaff.28.6.1642

55. HHS. HIV/AIDS glossary: life cycle. AIDSinfo. Accessed May 23, 2020.

56. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529-1541. doi:10.1038/s41375-018-0106-0

57. Vink CA, Counsell JR, Perocheau DP, et al. Eliminating HIV-1 packaging sequences from lentiviral vector proviruses enhances safety and expedites gene transfer for gene therapy. Mol Ther. 2017;25(8):1790-1804. doi:10.1016/j.ymthe.2017.04.028

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up